These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

743 related items for PubMed ID: 16964829

  • 21. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team.
    N Engl J Med; 2008 May 15; 358(20):2095-106. PubMed ID: 18480202
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A, EuroSIDA study group.
    HIV Med; 2011 May 15; 12(5):259-68. PubMed ID: 20812948
    [Abstract] [Full Text] [Related]

  • 24. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct 15; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V, MONOD Study Group.
    BMC Med; 2017 Apr 24; 15(1):85. PubMed ID: 28434406
    [Abstract] [Full Text] [Related]

  • 31. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 24; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 32. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I, Hernández-Novoa B, Alejos B, Santos I, Lopez-Aldeguer J, Riera M, Gutiérrez F, Rubio R, Antela A, Blanco JR, Moreno S, Cohort of the Spanish HIV Research Network (CoRIS).
    HIV Med; 2014 Oct 24; 15(9):547-56. PubMed ID: 24655804
    [Abstract] [Full Text] [Related]

  • 33. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov 24; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA, SECOND-LINE Study Group.
    Lancet HIV; 2017 Jan 24; 4(1):e13-e20. PubMed ID: 27815068
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA, SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    J Antimicrob Chemother; 2011 Nov 24; 66(11):2605-14. PubMed ID: 21903660
    [Abstract] [Full Text] [Related]

  • 39. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 40. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J, Yang R, Wirtz V, Sheppard L, Farajallah A, McGrath D.
    AIDS Care; 2011 Nov 31; 23(11):1500-4. PubMed ID: 21732894
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.